Indian pharma company Zydus has said it has started human studies for its potential Covid-19 vaccine. ZyCoV-D, its plasmid DNA vaccine, was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies. Zydus will enrol over 1,000 subjects across multiple clinical study sites in India in the human trials. Vaccines are awaited as coronavirus infections continue to surge in the world's third worst-hit nation. | The Times of India